Page 1

I - MAB BIOPHARMA I - Mab Provides Business and Corporate Updates and Reports Financial Results for the Six Months Ended June 30 , 2021 August 31 , 2021 • 13 significant clinical milestones achieved year - to - date , including critical positive data readout events for felzartamab ( TJ202 / MOR202 ) , lemzoparlimab ( TJC4 ) , uliledlimab ( TJD5 ) , and plonmarlimab ( TJM2 ) and more milestone achievements are expected before the year - end 2021 • Felzartamab ( TJ202 / MOR202 ) is on track for Biologic License Application ( BLA ) submission in Q4 2021 and eftansomatropin alfa ( TJ101 ) phase 3 trial on track for completion of patient enrollment and potential commercial collaboration • Growing pipeline with eight highly differentiated and clinically advanced assets in phase 2/3 , followed by next generation of immuno - oncology assets , including bi - specific antibodies in phase 1 or pre - clinical stage and novel drug candidates enabled by transformative technologies for unique drug properties , e.g. Al - guided targeting , antibody by mRNA delivery , intracellular targeting and tumor - site activation • Inclusion of the MSCI China All Shares Index , preparation of potential dual listing on China's STAR Market , and receiving of a high rating from the MSCI ESG assessment ( the highest newly initiated rating among China - based biotech companies ) • Progress in building the manufacturing and commercialization capabilities as part of Company's transformation to a global biopharma I - Mab to host conference calls and webcasts on August 31 , 2021. A Mandarin session conference call will be held at 7:00 a.m. ET , and an English session conference call will be held at 8:00 a.m. ET . SHANGHAI and GAITHERSBURG , Md . , Aug. 31 , 2021 / PRNewswire / -- I - Mab ( the " Company " ) ( Nasdaq : IMAB ) , a clinical stage biopharmaceutical company committed to the discovery , development and commercialization of novel biologics , today announced financial results for the six months ended June 30 , 2021 , and provided key business updates . During the reporting period , I - Mab has made remarkable progress in its key business areas . Firstly , on the R & D front , the Company has rapidly advanced its globally competitive pipeline and achieved all critical clinical milestones as set in early 2021 for the key pipeline assets . More specifically , the Company had seven clinical trials initiated or soon to be initiated , achieved five key data readout events for its differentiated investigational drugs , i.e. CD38 antibody felzartamab ( TJ202 / MOR202 ) , CD47 antibody lemzoparlimab ( TJC4 ) , CD73 antibody uliledlimab ( TJD5 ) , GM - CSF antibody plonmarlimab ( TJM2 ) and novel IL - 6 inhibitor olamkicept ( TJ301 ) . Furthermore , the Company has made significant progress in expanding the current pipeline through the bi - specific antibody panel , where two lead assets have advanced to clinical trials in the U.S. in early 2021 , as well as the next generation of novel antibody candidates enabled by transformative technologies through collaborations . In this regard , the Company has successfully entered into five technology partnering deals to gain access to cutting - edge technologies to generate novel drug molecules with uniquely acquired drug properties , including mRNA delivery , Al - guided targeting , cell - penetrating antibody and tumor - site activation . Secondly , on the corporate development front , the Company has met all expected corporate milestones with respect to building its manufacturing facility in Hangzhou and its commercialization capabilities and preparation of the market launch of felzartamab . I - Mab is now globally connected with six sites or offices in China and two R & D facilities in the U.S. Thirdly , during the reporting period , the Company has initiated its dual listing plan for the STAR Market in China and received multiple prestigious corporate honors by the global biotech community and the capital market . The Company also made efforts to further strengthen its Board of Directors and Scientific Advisory Board with internationally reputable experts . " With the corporate focus and execution by our highly committed team , I - Mab has managed to have successfully delivered outstanding results that have exceeded our original expectations set early this year , " said Dr. Jingwu Zang , Founder and Chairman of I - Mab . " We are thrilled by the achievements because many of the milestones are critical as they have provided positive and enabling clinical data needed for the further development of the key pipeline assets . Looking ahead , we will have 19 clinical trials either ongoing or soon to be initiated in both the United States and China by the end of this year , including our first BLA submission in Q4 2021. With these achievements , our pipeline is now not only innovative and globally competitive but also advanced with more assets moving towards late - stage clinical trials and BLA . " " The progress we have made so far has placed us firmly on track to deliver the rest of the critical milestones and has effectively secured our overall development plan for the key assets such as felzartamab , eftansomatropin alfa , lemzoparlimab , uliledlimab , and plonmarlimab . We are very excited and confident to succeed in our journey to transition from a clinical stage biotech now to a global biopharma within the next few years , " Dr. Zang concluded . Recent Pipeline Highlights and Upcoming Milestones